Printer Friendly

Breckenridge Pharmaceutical Inc signs licensing agreement with Impopharma.

M2 PHARMA-October 2, 2017-Breckenridge Pharmaceutical Inc signs licensing agreement with Impopharma

(C)2017 M2 COMMUNICATIONS

Pharmaceutical company Breckenridge Pharmaceutical Inc revealed on Friday the launch of a licensing agreement with Impopharma Inc for the generic version of its leading corticosteroid product.

Impopharma is the manufacturer of the generic ANDA of the corticosteroid product, which will be marketed and commercialised exclusively by Breckenridge for the US market.

According to the companies, the generic sales were in excess of USD25m of the corticosteroid product.

In conjunction, the product ANDA for its leading corticosteroid product has been filed and is pending final approval by the US Food and Drug Administration, concluded the company.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Oct 2, 2017
Words:121
Previous Article:Orexo enters into asset purchase agreement with Gesynta Pharma AB for OX-MPI.
Next Article:Wilson Therapeutics reports promising preliminary long-term data from WTX101 Phase 2 extension study to be presented at AASLD Annual Meeting.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters